Treatment of primary central nervous system lymphoma with cranial irradiation and combined modality therapy Chapter uri icon


MeSH Major

  • Antineoplastic Agents
  • DNA Repair
  • DNA, Neoplasm
  • Drug Resistance, Neoplasm
  • Eukaryotic Initiation Factor-2
  • Gene Expression Regulation, Neoplastic
  • TOR Serine-Threonine Kinases


  • © Springer Science+Business Media, LLC 2012. All rights reserved.Whole brain radiotherapy (WBRT) has long been recognized as an effective treatment for PCNSL. WBRT alone leads to tumor regression and prolongs median survival to approximately 12–18 months. However, disease returns in almost all patients. Adding chemotherapy to WBRT was the first step towards prolonging remission and survival in these patients. Through a series of studies, it is clear that high-dose methotrexate (MTX) is the single most effective agent for the treatment of PCNSL. However, whether MTX is used as a single agent or in combination with other drugs, it has the potential of causing long-term neurological sequelae when combined with WBRT, particularly in older patients. Recent data suggest that reducing the dose of WBRT may prove effective at enhancing disease control without causing neurotoxicity. Furthermore, WBRT remains an effective and important salvage therapy for those patients who recur after chemotherapy alone.

publication date

  • January 2012



  • Book Chapter


Digital Object Identifier (DOI)

  • 10.1007/9781441976680_7

Additional Document Info

start page

  • 129

end page

  • 139